News

Donanemab was approved by the FDA in July 2024 to treat adults with early symptomatic Alzheimer's disease with confirmed ...
Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...
The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...